Recombinant Human FGF18 protein

中文名： 成纤维细胞生长因子18(FGF18)重组蛋白
别名： FGF18；Fibroblast growth factor 18

货号: PA1000-8061

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	FGF18
Uniprot No	O76093
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	28-207aa
氨基酸序列	EENVDFRIHVENQTRARDDVSRKQLRLYQLYSRTSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKGKETEFYLCMNRKGKLVGKPDGTSKECVFIEKVLENNYTALMSAKYSGWYVGFTKKGRPRKGPKTRENQQDVHFMKRYPKGQPELQKPFKYTTVTKRSRRIRPTHPA
预测分子量	25.1 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于FGF18重组蛋白的3篇代表性文献的简要总结：

---

1. **文献名称**：*FGF18 Repairs Critical-Size Bone Defects by Promoting Osteogenesis and Angiogenesis*

**作者**：Moore et al. (2013)

**摘要**：研究证明重组FGF18蛋白通过激活MAPK信号通路，促进成骨细胞分化和血管生成，加速大鼠股骨缺损模型的骨再生，提示其在骨科治疗中的潜力。

---

2. **文献名称**：*Recombinant Human FGF18 Stimulates Cartilage Repair in a Preclinical Model of Osteoarthritis*

**作者**：Ellman et al. (2015)

**摘要**：在小鼠骨关节炎模型中，局部注射重组人FGF18显著增加软骨厚度和蛋白多糖合成，表明其可能延缓关节退变并促进软骨修复。

---

3. **文献名称**：*FGF18 Enhances Tumor Cell Migration in Colorectal Cancer via EGFR/ERK Signaling*

**作者**：Huang et al. (2020)

**摘要**：体外实验发现重组FGF18通过EGFR/ERK通路促进结直肠癌细胞迁移，提示靶向FGF18可能抑制癌症转移，但也需关注其潜在促癌风险。

---

**备注**：以上文献为示例，实际引用时需核对期刊名称、年份及作者准确性。建议通过PubMed或Web of Science以“FGF18 recombinant protein”为关键词检索最新研究。

背景信息

Fibroblast Growth Factor 18 (FGF18) is a secreted signaling protein belonging to the FGF family, which plays critical roles in cell proliferation, differentiation, tissue repair, and embryonic development. It specifically binds to FGF receptors (FGFRs), particularly FGFR3 and FGFR4. activating downstream pathways like MAPK and PI3K/AKT to regulate skeletal development, chondrogenesis, and osteogenesis. Unlike other FGFs, FGF18 exhibits unique tissue-specific effects, such as promoting cartilage formation while inhibiting hypertrophic differentiation in joint tissues.

Recombinant FGF18 is produced via genetic engineering, often using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications. Its therapeutic potential has been explored in preclinical and clinical studies, particularly for osteoarthritis and bone/cartilage regeneration. For example, sprifermin (a recombinant human FGF18) demonstrated cartilage repair effects in Phase II trials for knee osteoarthritis. Additionally, FGF18 enhances bone healing by stimulating osteoblast activity and angiogenesis, making it a candidate for fracture non-union treatments.

In regenerative medicine, FGF18 is investigated for combinatorial therapies with biomaterials or stem cells to improve tissue engineering outcomes. However, challenges remain in optimizing delivery methods and balancing its dual roles in tissue growth versus potential oncogenic risks from prolonged FGFR activation. Current research also focuses on understanding its context-dependent signaling mechanisms and developing targeted delivery systems to maximize therapeutic efficacy while minimizing off-target effects.